Labcorp to buy select assets from Opko Health unit for up to $872 million

Oct 15 (Reuters) — Laboratory operator Labcorp said on Thursday it will buy some assets from Opko Health's subsidiary in a $722 million cash deal, with a potential additional payment of up to $150 million tied to revenue from a prostate cancer test. Shares of Opko Health were up 20% in premarket trading. Here are some details: Under the agreement, Labcorp will acquire Opko's BioReference Health laboratory testing operations, including its clinical diagnostics, women's health, urology and corrections testing businesses Labcorp will gain more than 80 patient service centers and certain operating assets from the deal It will also get ownership of BioReference's 4Kscore test, which is used to help assess the likelihood of aggressive prostate cancer before a patient undergoes a biopsy. The test brought in revenue of $27.1 million in 2025 The Burlington, North Carolina-based company expects the acquired businesses to generate about $250 million in revenue in the first year after the transaction closes The deal requires regulatory clearance and other closing conditions. The companies did not provide an expected closing date Miami-based Opko said the sale will streamline its operations and